Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.

• Material Type: 文書・図像類
• Title: Monitoring of intracellular 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in 1-beta-D-arabinofuranosylcytosine therapy at low and conventional doses.
• Author/Editor: Yamauchi, Takahiro; Kawai, Yasukazu; Kishi, Shinji; Goto, Nobuyuki; Urasaki, Yoshimasa; Imamura, Shin; Fukushima, Toshihiro; Yoshida, Akira; Iwasaki, Hiromichi; Tsutani, Hiroshi; Masada, Mikio; Ueda, Takanori
• Author Heading: Yamauchi, Takahiro; Kawai, Yasukazu; Kishi, Shinji; Goto, Nobuyuki; Urasaki, Yoshimasa; Imamura, Shin; Fukushima, Toshihiro; Yoshida, Akira; Iwasaki, Hiromichi; Tsutani, Hiroshi; Masada, Mikio; Ueda, Takanori
• Publication, Distribution, etc.: Japanese Cancer Association
• Publication Date: 2001-05
• Publication Date (W3CDTF): 2001-05
• Periodical title: Japanese journal of cancer research : Gann
• No. or year of volume/issue: 92 5
• Volume: 92
• Issue: 5
• Pages: 546-553
• Text Language Code: eng
• Subject Heading: ara-C; ara-CTP; clinical pharmacokinetics; low and conventional dose
• Target Audience: 一般
• Note (General): 1-beta-D-Arabinofuranosylcytosine (ara-C) is used empirically at a low, conventional, or high dose. Ara-C therapy may be optimal if it is directed by the clinical pharmacokinetics of the intracellular active metabolite of ara-C, 1-beta-D-arabinofuranosylcytosine 5'-triphosphate (ara-CTP). However, ara-CTP has seldom been monitored during low- and conventional-dose ara-C therapies because detection methods were insufficiently sensitive. Here, with the use of our newly established method (Cancer Res., 56, 1800 -- 1804 (1996)), ara-CTP was monitored in leukemic cells from acute myelogenous leukemia patients receiving low- or conventional-dose ara-C [subcutaneous ara-C administration (10 mg / m(2) ) (3 patients), continuous ara-C infusion (20 or 70 mg / m(2) / 24 h) (7 patients), 2-h ara-C infusion (70 mg / m(2) ) (4 patients), and 2-h infusion of N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine, a deaminase-resistant ara-C derivative (70 mg / m(2) ) (6 patients)]. Ara-CTP could be determined at levels under 1 microM. There was a close correlation between the elimination half-life values of the plasma ara-C and the intracellular ara-CTP. The presence of ara-C in the plasma was important to maintain ara-CTP. The continuous ara-C and the 2-h N(4)-behenoyl-1-beta-D-arabinofuranosylcytosine infusions maintained ara-CTP and the plasma ara-C longer than the subcutaneous ara-C or the 2-h ara-C infusion. They also afforded relatively higher ara-CTP concentrations, and consequently produced ara-CTP more efficiently than the 2-h ara-C infusion. Different administration methods produced different quantities of ara-CTP even at the same dose.
• Access Restrictions: 限定公開
• Data Provider (Database): 国立情報学研究所 : 学術機関リポジトリデータベース（IRDB）（機関リポジトリ）; https://irdb.nii.ac.jp
• Original Data Provider (Database): 福井大学 : 福井大学学術機関リポジトリ